Proton Pump Inhibitor Therapy & Nivolumab Plus Ipilimumab in Melanoma Less Oncology Times. 41(2):37, January 20, 2019. Favorites PDF Get Content & Permissions
The COLUMBUS Trial in Metastatic Melanoma—New Peer-Reviewed Data Hamid, Omid Hamid, Omid Less Oncology Times. 41(1):1,8-9, January 5, 2019. Favorites PDF Get Content & Permissions
Combination Approach Shows Promise for Beating Advanced Melanoma Less Oncology Times. 40(18):36, September 20, 2018. Favorites PDF Get Content & Permissions
Combination Immunotherapy Shrinks Melanoma Brain Metastases Less Oncology Times. 40(18):35, September 20, 2018. Favorites PDF Get Content & Permissions
Newly Approved Combination Offers Hope for Metastatic Melanoma Kirkwood, John M. Kirkwood, John M. Less Oncology Times. 40(16):15,33-33, August 20, 2018. Favorites PDF Get Content & Permissions
Innovative CRISPR Study Recreates Genetic Steps in Melanoma Less Oncology Times. 40(15):28, August 5, 2018. Favorites PDF Get Content & Permissions
Trust Your Gut: The Microbiome & Metastatic Melanoma Holt, Chuck Holt, Chuck Less Oncology Times. 40(11):12-13, June 5, 2018. Favorites PDF Get Content & Permissions
Pembrolizumab Shows Reduced Risk for Recurrence in Melanoma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(10):33, May 20, 2018. Favorites PDF Get Content & Permissions
The Reality of Precision Medicine in Metastatic Melanoma Weber, Jeffrey S. Weber, Jeffrey S. Less Oncology Times. 40(6):1-5, March 20, 2018. Favorites PDF Get Content & Permissions
Presurgical Targeted Therapy Delays Relapse of High-Risk Stage III Melanoma Less Oncology Times. 40(3):27, February 5, 2018. Favorites PDF Get Content & Permissions
Molecular Profiling Explains Survival of Melanoma Cells After Therapy Less Oncology Times. 39(24):33, December 25, 2017. Favorites PDF Get Content & Permissions
Gut Bacteria Modulates Response to Immunotherapy in Melanoma Less Oncology Times. 39(22):49, November 25, 2017. Favorites PDF Get Content & Permissions
Adjuvant Nivolumab Superior to Ipilimumab in High-Risk Melanoma Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 39(21):37, November 10, 2017. Favorites PDF Get Content & Permissions
Melanoma Cells Rewire to Resist Drug Treatment Less Oncology Times. 39(21):24, November 10, 2017. Favorites PDF Get Content & Permissions
Binimetinib & Encorafenib for Patients With Melanoma Less Oncology Times. 39(20):25, October 25, 2017. Favorites PDF Get Content & Permissions
Immune-Cell Numbers Predict Response to Combination Immunotherapy in Melanoma Less Oncology Times. 39(15):32, August 10th, 2017. Favorites PDF Get Content & Permissions
Long-Term Survival Extended in Advanced Melanoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(13):32, July 10th, 2017. Favorites PDF Get Content & Permissions
FDA Approves First Treatment for Rare Form of Skin Cancer Less Oncology Times. 39(9):36, May 10th, 2017. Favorites PDF Get Content & Permissions
Electronic Brachytherapy for Nonmelanoma Skin Cancer Stegman, Lauren D. Stegman, Lauren D. Less Oncology Times. 39(9):38-39, May 10th, 2017. Favorites PDF Get Content & Permissions
ImmunoPulse IL-12 Receives Fast Track Designation for Melanoma Less Oncology Times. 39(7):4, April 10th, 2017. Favorites PDF Get Content & Permissions
Translation Reprogramming Key Determinant of Melanoma Invasion Goding, Colin Goding, Colin Less Oncology Times. 39(6):1,8-8, March 25th, 2017. Favorites PDF Get Content & Permissions
Patient Self Checks Are Critical to Avoid Melanoma Recurrence Less Oncology Times. 39(5):18, March 10th, 2017. Favorites PDF Get Content & Permissions
Combination Therapy for Metastatic Melanoma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 39(2):1,8-9, January 25th, 2017. Favorites PDF Get Content & Permissions
Predicting Patient Responses to Melanoma Treatment Less Oncology Times. 38(23):38,42-42, December 10th, 2016. Favorites PDF Get Content & Permissions
Anti-IDO1 Combination Improves Progression-Free Melanoma Survival Samson, Kurt Samson, Kurt Less Oncology Times. 38(23):22, December 10th, 2016. Favorites PDF Get Content & Permissions
Adjuvant Ipilimumab Brings Longer Survival With Stage III Melanoma Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 38(22):38,41-41, November 25th, 2016. Favorites PDF Get Content & Permissions
How Does Melanoma Spread to Other Organs in the Body? Less Oncology Times. 38(17):16, September 10th, 2016. Favorites PDF Get Content & Permissions
Optical Coherence Tomography for Skin Cancer Wang, Katie; Levine, Amanda; Markowitz, Orit Wang, Katie; Levine, Amanda; Markowitz, Orit Less Oncology Times. 38(17):15-16, September 10th, 2016. Favorites PDF Get Content & Permissions
Dabrafenib Plus Trametinib Improves Survival in Advanced Melanoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(13):16, July 10th, 2016. Favorites PDF Get Content & Permissions
Merkel Cell Carcinoma Responds to PD-1 Inhibitor Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 38(12):27, June 25th, 2016. Favorites PDF Get Content & Permissions
Phosphodiesterase Inhibitors Linked to Melanoma Susman, Ed Susman, Ed Less Oncology Times. 38(11):27, June 10th, 2016. Favorites PDF Get Content & Permissions
Ski Slopes & Cane Fields Present Melanoma Risks Susman, Ed Susman, Ed Less Oncology Times. 38(11):26, June 10th, 2016. Favorites PDF Get Content & Permissions
Melanoma Immunotherapy: We've Come a Long Way O'Donnell-Tormey, Jill O'Donnell-Tormey, Jill Less Oncology Times. 38(8):1,9,21-21, April 25th, 2016. Favorites PDF Get Content & Permissions
FDA Approves Opdivo-Yervoy Combo, Opdivo Single-Agent Therapy for New Indications in Metastatic Melanoma Less Oncology Times. 38(4):24, February 25th, 2016. Favorites PDF Get Content & Permissions
FDA Approves Tafinlar+Mekinist Combo for Melanoma Less Oncology Times. 38(3):35, February 10th, 2016. Favorites PDF Get Content & Permissions
FDA Approves Keytruda for Melanoma Less Oncology Times. 38(2):27, January 25th, 2016. Favorites PDF Get Content & Permissions
POINT-COUNTERPOINT: Does Sentinel Lymph Node Biopsy Extend Survival in Melanoma? Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(2):28-29, January 25th, 2016. Favorites PDF Get Content & Permissions
FDA Approves Opdivo as Single Agent for Melanoma Less Oncology Times. 38(1):41, January 10th, 2016. Favorites PDF Get Content & Permissions
FDA Breakthrough Therapy Designation to Avelumab for Merkel Cell Carcinoma Less Oncology Times. 37(24):32, December 25th, 2015. Favorites PDF Get Content & Permissions
Indications that Radiation Can Enhance Immunotherapy's Effects in Metastatic Melanoma Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 37(24):38, December 25th, 2015. Favorites PDF Get Content & Permissions
FDA Approves Cotellic Combo Therapy for Advanced Melanoma Less Oncology Times. 37(23):57, December 10th, 2015. Favorites PDF Get Content & Permissions
FDA Approves First Oncolytic Virus Therapy: Imlygic for Melanoma Less Oncology Times. 37(23):36, December 10th, 2015. Favorites PDF Get Content & Permissions
Ipilimumab Approved for Adjuvant Use in Melanoma Less Oncology Times. 37(23):2, December 10th, 2015. Favorites PDF Get Content & Permissions
Opdivo-Yervoy Combination Approved for Melanoma—First Combination-Immunotherapy Regimen for Cancer Less Oncology Times. 37(21):39, November 10th, 2015. Favorites PDF Get Content & Permissions
The Lymphoma-Melanoma Connection Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(18):1,26-28, September 25th, 2015. Favorites PDF Get Content & Permissions
Priority Review to Keytruda for First-Line Treatment of Advanced Melanoma Less Oncology Times. 37(17):40, September 10th, 2015. Favorites PDF Get Content & Permissions
Melanoma: Amid Caveats, New Test Predicts Metastasis and Survival Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(17):26-29, September 10th, 2015. Favorites PDF Get Content & Permissions
Weighing Treatment Decisions in Melanoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(16):16-17, August 25th, 2015. Favorites PDF Get Content & Permissions
